Dublin, Feb. 13, 2017 -- Research and Markets has announced the addition of the "Handheld Devices for High Viscosity Injectables" report to their offering.
Growth in high viscosity drugs is being driven by advances in biotechnology and host-vector engineering - advances that have led to a steady stream of biologics for a number of ailments and conditions. These powerful drugs come with a high cost-per-dose and the risk of significant side effects - factors that place an elevated emphasis on administration efficiency, safety and reliability.
Many drugs in this class are characterized by physical properties and sensitivities that challenge the drug commercialization ecosystem. For example, monoclonal antibodies, perhaps the most significant category in terms of therapeutic and commercial importance, typically possess viscosities that are well above the normal limits of subcutaneous injection devices and techniques.
Without a technical solution, these high viscosity drugs are formulated and supplied for infusion, a trend that threatens to put additional pressure on patient logistics and healthcare economics. Drug developers and device designers are increasingly working in collaboration to address the goal of subcutaneous administration of high viscosity injectables.
Handheld Devices for High Viscosity Injectables - What You Will Learn
- What are the markets for therapeutic drugs with viscosities that cannot be delivered using standard self-injection devices and techniques?
- What are the technologies and devices that are aimed at positioning high viscosity drugs for subcutaneous injection?
- What are the design factors, material selection issues, formulation factors, and device capabilities and limitations of handheld devices that address the limitations of high viscosity drugs?
- Who are the high viscosity injectable drug and device participants, their product development activities, business strategies, and corporate alliances and affiliations?
- What are the key therapeutic sectors for high viscosity injectables?
- What does the market for high viscosity injectables look like today? What will it be in 2020?
- What is the impact of economic, technology, and regulatory factors on high viscosity drugs that can be administered via handheld devices?
Key Topics Covered:
1. Executive Summary
2. The Market Opportunity
3. High Viscosity Drug Market Dynamics
- The Economics of Drug Delivery
- Market Drivers
- Growth of Biological Drugs
- Demographics and Disease Prevalence
- Innovation in Handheld Devices
- Managed Care and Healthcare Economics
- Competitive Landscape
- Risk Factors
4. High Viscosity Injection Devices - Design Factors
- Drug Properties
- Drug Storage Requirements
- Baseline Device Capabilities
- Primary Packaging
- Human Engineering/Ergonomics
- Formulation Technology
5. High Viscosity Drugs - Addressable Markets
- Legacy Drugs - IV-to-Subcutaneous Migration
- Biologicals
- Drugs Currently Approved for Infusion
- Development-stage Biologicals
- Formulation-related High Viscosity
- Sustained Release Injectables
- Solubility-enhanced Formulations
6. Analysis of High Viscosity-Capable Handheld Devices
- Specialty Glass Syringes
- Specialty Autoinjectors
- Cyclic Olefin Prefillable Syringes
- Formulation-specific Devices
7. Near-term Therapeutic Sector Analysis
- Therapy Sectors
- Forecasts and Prospects
8. Market Factors
- Regulatory Issues
- Device Branding
- Quality by Design
- Ease of Use
9. Company Profiles
For more information about this report visit http://www.researchandmarkets.com/research/km5gv3/handheld_devices
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Infusions and Injectables


Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S.
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 



